|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
CSL Limited |
| Information provided by: | CSL Limited |
| ClinicalTrials.gov Identifier: | NCT00225719 |
Purpose
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (IVUS) in patients after acute coronary syndromes (ACS).
| Condition | Intervention | Phase |
|
Acute Coronary Syndromes |
Drug: rHDL |
Phase II |
| MedlinePlus related topics: | Ultrasound |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound. |
Eligibility
| Ages Eligible for Study: | 30 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | CSLCT-HDL-04-06 |
| First Received: | September 23, 2005 |
| Last Updated: | May 28, 2007 |
| ClinicalTrials.gov Identifier: | NCT00225719 |
| Health Authority: | Canada: Health Canada |
|
|
|